Intracellular delivery of heparin complexed with chitosan-g-poly(ethylene glycol) for inducing apoptosis.
OBJECTIVE
Chitosan-g-PEG/heparin polyelectrolyte complex micelles were prepared for inducing apoptotic death of cancer cells.


METHODS
The cytotoxicity of polyelectrolyte complex micelles was evaluated by examining the growth inhibition of mouse melanoma B16F10 cells. Cellular uptake and apoptosis-inducing effect were investigated by confocal laser scanning microscopy and flow cytometric analysis, respectively.


RESULTS
The prepared polyelectrolyte complex micelles had a spherical shape with an average diameter of 162.8 +/- 18.9 nm. They were highly stable and well dispersed even in the presence of serum due to the presence of hydrophilic PEG shell layer surrounding the micelles. Moreover, they exhibited significantly higher cytotoxic activity against B16F10 cells compared to heparin or chitosan-g-PEG at the same concentration. The polyelectrolyte complex micelles were internalized by cancer cells to a greater extent than free heparin alone, indicating that the dramatic cell death was attributed to the increased cellular uptake of heparin. The internalized heparin was shown to induce apoptotic death of the cancer cells via a caspase-dependent pathway.


CONCLUSIONS
Nanosized and stable chitosan-g-PEG/heparin polyelectrolyte complex micelles were produced by a self-assembly process. The polyelectrolyte complex micelles facilitated the intracellular delivery of heparin, triggered the caspase activation, and consequently promoted apoptotic death of cancer cells.
Bae
Ki Hyun
KH
Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 305-701, South Korea.
Moon
Chang Won
CW
Lee
Yuhan
Y
Park
Tae Gwan
TG
D000818:Animals; D000970:Antineoplastic Agents; D017209:Apoptosis / Q000187:drug effects*; D002240:Carbohydrate Sequence; D045744:Cell Line, Tumor; D048271:Chitosan / Q000737:chemistry*; D005079:Excipients / Q000737:chemistry*; D005434:Flow Cytometry; D006493:Heparin / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology*; D008027:Light; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008823:Micelles; D018625:Microscopy, Atomic Force; D011092:Polyethylene Glycols / Q000737:chemistry*; D012542:Scattering, Radiation
D000970:Antineoplastic Agents; D005079:Excipients; D008823:Micelles; D011092:Polyethylene Glycols; D006493:Heparin; D048271:Chitosan
J Control Release. 1998 Jun;54(1):39-48
9741902
Eur J Pharm Biopharm. 1999 Sep;48(2):101-11
10469928
J Control Release. 2005 Nov 2;108(1):121-31
16139916
Nature. 2000 Oct 12;407(6805):770-6
11048727
Mol Biol Cell. 1993 Sep;4(9):953-61
8257797
Cytometry. 1992;13(8):795-808
1333943
Biomacromolecules. 2007 Jan;8(1):146-52
17206800
Nat Rev Drug Discov. 2003 May;2(5):347-60
12750738
Science. 1994 Mar 18;263(5153):1600-3
8128245
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3352-7
11248082
J Gene Med. 2006 Apr;8(4):477-87
16389625
Pharm Res. 2007 Aug;24(8):1405-14
17393074
Pharm Res. 2007 Apr;24(4):705-14
17318418
Clin Cancer Res. 2005 Nov 15;11(22):8172-9
16299249
Biomacromolecules. 2001 Winter;2(4):1178-83
11777390
Chem Biol. 2004 Apr;11(4):487-98
15123243
J Biomed Mater Res A. 2007 Dec 1;83(3):806-12
17559117
Eur J Pharm Biopharm. 2004 Jan;57(1):35-52
14729079
Pharm Res. 2002 Jun;19(6):810-7
12134951
Biomaterials. 2007 Jun;28(16):2667-76
17335894
Nat Rev Cancer. 2002 Jul;2(7):521-8
12094238
Biomaterials. 2008 Aug;29(23):3376-83
18474396
Bioconjug Chem. 2006 Sep-Oct;17(5):1209-18
16984130
Adv Drug Deliv Rev. 2001 Nov 5;52(2):117-26
11718935
Adv Drug Deliv Rev. 2006 Jul 7;58(4):467-86
16781003
J Control Release. 2004 Nov 5;100(1):5-28
15491807
Annu Rev Biochem. 1999;68:383-424
10872455
Bioconjug Chem. 1995 Jan-Feb;6(1):7-20
7711106
J Control Release. 2006 Apr 10;111(3):299-308
16481062
Science. 2003 Apr 25;300(5619):595-6
12714733
Adv Drug Deliv Rev. 2002 Feb 21;54(2):203-22
11897146
Nat Rev Drug Discov. 2003 Mar;2(3):214-21
12612647